Orgenesis is a pioneering global biotech company featuring a unique Cell & Gene Therapy Biotech Platform. The company is focused on unlocking the power of cell and gene therapies with this platform to provide life changing treatments at the Point of Care (POCare) to large numbers of patients at drastically reduced costs. The Platform consists of a pipeline of POCare Therapeutics; a suite of hand-selected and customized POCare Technologies for closed processing; and a collaborative, global POCare Network of leading companies, research institutes and hospitals. Working with this Platform, Orgenesis leverages cutting edge science to create a more efficient, scalable, and affordable pathway to patients. In June 2019, Orgenesis was granted an FDA orphan drug designation for its autologous insulin-producing cells.